Rapid Readouts: Final Analysis Results From the Phase 3 TITAN Study

Video

Kim N. Chi, MD, presents slides from the 2021 ASCO Genitourinary Cancers Symposium for the final results from the phase 3 TITAN study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.

Related Videos
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Josep Maria Piulats Rodriguez, MD, PhD
Phillip J. Koo, MD
Phillip J. Koo, MD
Gautam Jha, MD
Emmanuel Antonarakis, MD, and Gautam Jha, MD
Related Content
Ebrahim Delpassand, MD, of Excel Diagnostics and Nuclear Oncology Center

PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC

April 10th 2024
Article
Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023
Podcast
Ruben Olivares, MD

Patient Selection Key for Focal Therapy in Intermediate Prostate Cancer

April 5th 2024
Article
Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023
Podcast
Daniel Spratt, MD, of University Hospitals Seidman Cancer Center and Case Western Reserve University

Metastasis-Directed Radiotherapy Represents Significant Advancement in Prostate Cancer

April 4th 2024
Article
Phillip J. Koo, MD, chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona

Recommendations Further Aid in Elucidating the Role of PSMA PET Imaging in Prostate Cancer

April 3rd 2024
Article